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A B S T R A C T
Chronically hemodialyzed (HD) patients frequently suffer from quantitative and even more often qualitative serum
lipids disorders. Mostly they have increased triglycerides and VLDL-cholesterol, slightly increased or normal total and
LDL-cholesterol and decreased HDL-cholesterol concentrations. The study compared lipid profile between two groups of
chronic HD patients coming from regionally distinct areas, the continental and the maritime one. The aim was to exam-
ine the hypothetic influence of their different dietary habits on lipid profile. The study included 72 patients from continen-
tal region (39 men) and 50 from maritime part of the country (30 men). Patients suffering from diabetes mellitus, hypo-
thyroidism, liver disease, alcoholics as well as sevelamer treated patients were not included. Prior to a HD session the
patients were determined fasting total cholesterol, triglycerides, HDL- and LDL-cholesterol, total proteins, albumins and
C-reactive protein serum concentrations. All patients were undergoing bicarbonate hemodialysis with polysulphone dia-
lysers of low permeability. The continental group of patients were somewhat older, undergoing HD for longer period of time,
of lower height, greater weight, greater body mass index, higher total (4.70±0.91: 4.42±1.02 mmol/L), and LDL-cholesterol
(2.78±0.74:2.66±0.75 mmol/L) concentrations, while lower triglycerides (1.72±0.84:1.81±0.83 mmol/L) and HDL-choles-
terol (1.13±0.42:1.16±0.54 mmol/L). However, all the differences were without statistical significance. Chi-square test sho-
wed that the continental group of patients consumed more often pork, bacon, smoked and cured meats, margarine, butter,
walnuts, almonds, garlic, cream and full-fat cheese than fish. They prepare food more often with lard and sunflower oil.
Almost every fourth continental patient received statins, while only every 25th in the maritime group of patients. There were
not any statistically significant Chi-square values for differences in frequencies of patients with total cholesterol greater
than 5.2 mmol/L, triglycerides above 1.6 mmol/L, HDL-cholesterol less than 1.1 mmol/L, LDL-cholesterol greater than 2.6
mmol/L, obesity and malnutrition between the two groups. Based on the results of this study we have concluded that diet
has significant influence on lipid profile of HD patients. Even though the continental and the maritime groups of patients
differed significantly in diet, they were similar in plasmatic lipoprotein concentrations. However, this similarity was as-
cribed only to statin treatment, which was more frequent in the continental group of patients. The influence of ESRD and
HD as a method of renal replacement therapy on lipid profile was not more dominant than diet.
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Introduction
Final stage chronic renal failure patients very often
suffer from quantitative (hyperlipoproteinemia), and even
more frequently from qualitative disorders of plasma
lipoproteins (dyslipoproteinemia or dyslipidemia). Mostly
they have increased triglycerides (TGC) and VLDL-cho-
lesterol (VLDL-C), slightly increased or normal total
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(TC) and LDL-cholesterol (LDL-C) and decreased HDL-
-cholesterol (HDL-C) concentrations1–4. This represent a
characteristic feature of renal failure itself, although ad-
ditional influences are displayed by the basic renal dis-
ease, as well as the cause of renal failure and the method
of treatment. For that reason, there are differences in
plasma lipoprotein disorders between hemodialyzed pa-
tients and those treated by peritoneal dialysis. Those dif-
ferences occur early, following the decrease of glomerular
filtration below 50 mL/min/1.73 m2 of body surface area5.
Numerous studies showed that 20% of hemodialyzed pa-
tients and 5% of patients treated by peritoneal dialysis
have total cholesterol (TC) above 6.2 mmol/L, 30% i.e.
45% LDL-C above 3.4 mmol/L, 45% i.e. 50% TGC above
2.3 mmol/L and 50% i.e. 20% of them HDL-C below 0.9
mmol/L6,7. According to data from American Society of
Nephrology approximately 25% of hemodialyzed and 60%
of patients treated by peritoneal dialysis have TGC above
2.26 mmol/L, 70% i.e. 76% LDL-C above 2.60 mmol/L,
and 50% of hemodialyzed patients has non-HDL-C above
3.4 mmol/L.8 They occur due to decreased activity of
three key enzymes, important for lipid metabolism, lipo-
protein lipase (LPL), hepatic triglyceride lipase (HTGL)
and lecithin cholesterol acyltranferase (LCAT)9–11.
Plasma lipoprotein disorders are firmly correlated
with cardiovascular diseases, which are the leading cause
of death for this group of patients12. It has been esti-
mated that 40–50% of dialyzed patienst die from cardio-
vascular accidents13 and that the mortality of patients
with final stage of CRF frommyocardial infarction, heart
failure and stroke is 10–20 times greater when compared
to the mortality in general population of comparable age
and gender14–16. There are numerous studies which prove
that the treatment of plasma lipoprotein disorders in pa-
tients without CRF17–19, especially hypercholesterolemia,
leads to the decrease not only of the mortality from car-
diovascular accidents, but also to the decrease of general
mortality, for both the patients with diagnosed17,18 and the
patients without diagnosed cardiovascular diseases19,20.
Although the relationship between cholesterol and ath-
erosclerosis in patients with CRF is less clear than in
general population, Selger et al.21 has established that
the treatment of plasma lipoprotein disorders signifi-
cantly decreases both the mortality from cardiovascular
diseases and general mortality of dialyzed patients. Na-
mely, during 1000 years of dialysis treatment 143 pa-
tients treated with statins, and 202 patients not treated
with statins have died. The difference is statistically sig-
nificant. The use of statins decreased the relative mortal-
ity risk by 32%. Similar was also the effect on cardiovas-
cular mortality (during 1000 years of dialysis treatment
61 patients who had been using statins and 88 patients
who have not been using this medication, died). The au-
thors conclude that statins in these groups of patients ex-
hibit protective influence regardless whether they have
or do not have elevated levels of total cholesterol and
LDL-C. After having performed the analysis of statin in-
fluence on treatment outcome for a large group of hemo-
dialyzed patients (longitudinal follow up of approxima-
tely 30,000 patients, successively included in the period
1996–2005, in more than 300 centres for dialysis, in 12
countries on 4 continents – Dialysis Outcomes and Prac-
tise Patterns Study – DOPPS), Mason et al.22 have con-
cluded that every increase in frequency of statin use by
10% decreases the general mortality rate by 5%. How-
ever, the correlation between the risk of coronary disease
emergence and cholesterol level in hemodialyzed pa-
tients is not linear as is in general population. Hemo-
dialyzed patients with total cholesterol below 2.6 mmol/L
have 4.3 times greater mortality than the patients with
total cholesterol between 5.2 and 6.5 mmol/L23.
There are three steps in treating plasma lipoprotein
disorders, and they are applied almost independently to
the cause which provoked them24. Those are: adequate
diet, workout and pharmacological medications which in-
fluence the level of plasma lipoproteins. Adequate diet is
the one poor with saturated fatty acids. Workout, if toler-
ated and performed by patients over a longer period of
time, definitely improves lipid profile, as well as glucose
tolerance in selected group of patients25–27. Nevertheless,
it is not known whether the workout decreases mortality
in this group of patients24. Hemodialyzed patients have
decreased ratio of subcutaneous and increased ratio of
visceral adipose tissue compared to body mass index
(BMI)28. The best survival rate is observed among hemo-
dialyzed patients with BMI between 27.5 i 30.0 kg/m2
body surface area29,30. The goal of the treatment was to
accomplish the level of LDL-C below 2.6 mmol/L, TGC
below 2.0 mmol/L and total cholesterol (TC) above 3.9
mmol/L24. The recommendation is that the treatment
with hydroxy-beta-methyl-glutaryl coenzyme A (HMG-
-CoA), i.e. statins, should start if target levels of specific
plasma lipoproteins24 have not been achieved after a
3-month diet and workout. If the level of LDL-C remains
above 2.6 mmol/L after a 6-week statin therapy, the
statin dosage is being gradually increased over another
6-week period. Should the LDL-C level remain above 2.6
mmol/L after that period of time, there is indication for
introduction of nicotinic acid31 or sevelamer hydrochlori-
de32, phosphate binder, which decrease LDL-C by 5–25%31,
i.e. by 20–30%32, Patients with TGC between 2.0 i 5.7
mmol/L are recommended to use inhibitors HMG-CoA
reductase, those with TGC above 5.7 and 9.0 mmol/L
analogs of fibric acid, and to those with TGC above 9.0
mmol/L fish oil and low-molecule heparin24.
In this paper we compared lipoprotein profile of two
groups of hemodialyzed patients, from continental and
maritime region, whose dietary habits differ significantly
in types of food they consume as well as in the methods of
food preparation. Patients from the continental group of-
ten eat pork, and they prepare the food using lard or sun-
flower oil. Patients from maritime group, on contrary,
very often eat fish, and prepare their food either without
oil or with olive oil. Our goal was to determine whether
the patient groups in our study differ in lipoprotein pro-
file and to what extent are possible differences influ-
enced by their dietary habits.
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Subjects and Methods
The study included 122 patients (53 females, 69 ma-
les) suffering from final stage CRF undergoing bicarbon-
ate dialysis with polysulphone dialysers of low perme-
ability three times a week (surface area 1.5–2.0 m2,
ultrafilatration index 9.8–13.7 mL/mmHg of transmem-
brane pressure/hour), usual blood flow rate (250–350
mL/minuti) and dialysate (500 mL/minute). To prevent
blood coagulation in extracorporeal dialytic circuit all pa-
tients received classical sodium heparin. Patients in-
cluded in the study were treated in three Centres for Di-
alysis. Two Centres were located in the continental re-
gion and one was located in the maritime part of Croatia.
The patients from two continental Centres made up the
continental group of patients (n=72), and the patients
from the maritime Centre made up the maritime group
of patients (n=50). Patients suffering from diabetes me-
llitus, hypothyroidism, liver disease, alcoholics as well as
sevelamer treated patients were not included.
Along with the basic data (age, gender, the date of the
hemodialysis treatment start), before their regular he-
modialysis, each fasting patient was tested for a set of
laboratory parameters: total cholesterol (CHOD PAP
method – reference values 3–5.2 mmol/L), triglycerides
(GPO PAP method – reference values 0.6–1.7 mmol/L),
HDL-cholesterol (precipitation with phosphowolframate
and magnesium ion – reference values for women above
1.6 mmol/L, and for men above 1.4 mmol/L), LDL-choles-
terol (for triglyceride values below 3.0 mmol/L it was cal-
culated mathematically using Friedewald formula33, and
for triglyceride values above 3.0 mmol/L it was calculated
using precipitation method with polyvinil sulphate– ref-
erence values up to 3.5 mmol/ l), total proteins (Cologel
method– reference values 64–82 g/L), albumin (BCG
method – reference values 35–52 g/L), hemoglobin (auto-
mated cell counter – reference values 119–157 g/L for
women, 138–175 g/L for men) and C-reactive protein –
immunoturbidimetric method, Boehringer, Manheim –
reference values up to 5.0 mg/L), body weight (kg) and
body height (cm). Body Mass Index (BMI)34 was calcu-
lated from body weight and body height.
All patients anonymously filled out a questionnaire
requesting data about their dietary habits. Basically, pa-
tients were asked to answer whether they consume: 1.
pork, 2. bacon, 3. smoked and cured meat, 4. fish, 5. mar-
garine, 6. butter, 7. coffee, 8. walnuts, almonds, hazel-
nuts, peanuts, 9. garlic, 10. cream and full-fat cheese a)
daily b) every other day, c) twice a week d) once a week or
e) even less frequently. They were also asked if they used
lard, sunflower oil, olive oil or any other vegetable oil in
food preparation. From patients’ medical records as well
as interviews we have learned which one of them take
hypolipemic medications, b-blockers, diuretics and eryth-
ropoietin.
The obtained individual results were expressed as
arithmetic means, standard deviations and percentages.
They have been analyzed by means of Student’s t-test
for independent samples and c2-test. The level of statis-
tical significance was set from 1 and 5% (p<0.01 and
p<0.05)35.
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TABLE 1





X±SD range X±SD range
Age (years) 59.68±15.83 24–84 58.89±15.24 26–81 0.28
HD (months) 75.48±60.54 3–261 65.28±49.19 9–204 1.02
Gender (f/m) 33/39 20/30 a0.21
Height (cm) 167±10 150–190 168±12 140–192 0.48
Weight (kg) 68.18±14.32 43.50–115 65.59±12.74 38–91 1.05
BMI (kg/m2) 24.46±4.20 16.28–38.54 23.18±3.49 14.29–31.62 1.83
Tot.-C (mmol/L) 4.70±0.91 2.92–6.54 4.42±1.02 2.04–6.59 1.56
TGC (mmol/L) 1.72±0.84 0.64–6.22 1.81±0.89 0.68–4.07 0.56
HDL-C (mmol/L) 1.13±0.42 0.62–3.70 1.16±0.54 0.55–3.98 0.33
LDL-C (mmol/L) 2.78±0.74 1.39–4.49 2.66±0.75 0.93–4.20 0.87
Haemoglobin (g/L) 98.25±7.12 70–127 96.42±6.85 68–123 1.43
Tot. proteins (g/L) 67.99±4.76 55.70–77 69.11±5.04 60–81.40 1.23
Albumin (g/L) 41.47±3.44 33.3–49.8 41.21±2.67 36.6–48.50 0.47
CRP (mg/L) 8.94±10.58 1.30–46.70 7.61±10.86 1.50–68 0.67
Heparin (UI) 3590±1319 2000–7000 3296±946 2000–5500 1.78
a c2-test; BMI – body mass index, Tot.-C – total cholesterol, TGC – triglycerides, HDL-C – HDL-cholesterol, LDL-C – LDL-cholesterol,
CRP – C-reactive protein
Results
The patients from the continental group (n=72; fe-
males 33, males 39) compared to the patients from the
maritime group (n=50; females 20, males 30) were some-
what older, undergoing HD for longer period of time, of
lower height, greater weight, greater BMI, higher TC
(4.70±0.91:4.42±1.02 mmol/L) and LDL-C (2.78±0.74:
2.66±0.75 mmol/L), haemoglobin, C-reactive protein and
albumin, and lower TGC (1.72±0.84:1.81±0.83 mmol/L),
HDL-C (1.13±0.42:1.16±0.54 mmol/L) and total proteins.
According to Student’s t-test differences were not statis-
tically significant (Table 1). According to c2-test statisti-
cally significant was the fact that the patients from the
continental group consumed more often pork, bacon,
smoked and cured meat, margarine, butter, walnuts, al-
monds, garlic, cream and full-fat cheese, and rarely fish.
It is also significant that they more frequently prepared
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TABLE 2
BASIC DATA ON THE FREQUENCY OF CONSUMPTION OF CERTAIN FOODS AND ON THE METHODS OF FOOD PREPARATION








Food a b c d e a b c d e
1.Pork 2 12 22 22 14 0 0 1 15 34 40.17**
2. Bacon 1 6 12 8 46 0 0 2 0 46 18.89**
3. Smoked and cured meat 8 12 8 10 34 0 6 13 12 19 11.68**
4. Fish 0 4 6 40 22 1 4 25 17 3 30.51**
5. Butter 8 8 18 2 36 0 2 2 1 45 22.50**
6. Margarine 20 16 14 6 16 1 2 11 7 29 29.26**
7. Black coffee 42 4 8 6 12 30 4 2 0 14 8.05
8. Walnuts, almonds, hazelnuts, peanuts 4 4 2 10 52 0 0 0 0 50 16.61**
9. Garlic 4 10 6 10 42 0 4 13 4 29 10.48**
10. Cream and cheese 6 14 14 20 18 0 0 2 0 48 60.64**
Methods of foods preparation
aa bb cc dd aa bb cc Dd
Number of patients 8 24 62 6 50 0 1 2 111.57**
TABLE 3
BASIC DATA ON SOME OF THE EXAMINED PARAMETERS IN THE TWO GROUPS OF HEMODIALYZED PATIETNS






Tot. cholesterol above 5.20 mmol/L 22 10 0.73
Triglycerides above 1.60 mmol/L 42 27 0.08
HDL-cholesterol below1.10 mmol/L 41 32 0.35
LDL-cholesterol above 2.60 mmol/L 44 28 0.05
CRP above 5 mL/L 36 15 3.30
Males 39 30 0.21
BMI above 25 kg/m2 27 13 1.29
BMI above 30 kg/m2 7 3 0.16
BMI under 20 kg/m2 7 11 2.63
BMI 20–25 kg/m2 38 13 1.29
Treatment with statins 17 2 **7.20
Erythropoietin therapy 28 43 0.05
CRP – C-reactive protein, BMI – body mass index
food using sunflower oil and lard (Table 2). Almost every
fourth patient form the continental group received statins
(n=17; 23.61%), in comparison to only every twenty-fifth
from the maritime group(n=2; 4%). There was not any
statistically significant difference in frequency of taking
b-blockers, diuretics and erythropoietin.
According to c2-test there was not any statistically
significant difference between groups of patients con-
cerning the frequency of patients with TC above 5.2
mmol/L, TGC above 1.6 mmol/L, HDL-C below 1.10
mmol/L, LDL-C above 2.60 mmol/L, those with BMI
above 25 or 30 as well as those under 20 kg/m2 (Table 3).
When the patients receiving statins were excluded
from the studied groups of patients it has been observed
that the differences in mean values of TC, TGC, HDL-C
and LDL-C in new formed groups (continental n=55,
maritime n=48) were even smaller for 3 out of 4 ob-
served parameters (Table 4). Mean TC of the patients
from the continental group receiving statins (n=17) was
5.29±0.97 mmol/L, TGC was 2.16±0.70 mmol/L, HDL-C
1.05±0.27 mmol/L, and LDL-C 3.21±0.73 mmol/L. Mean
values of the above-mentioned parameters for two pa-
tients from themaritime group were 6.35±0.08, 2.38±1.87,
1.06±0.02, 3.95±0.23 mmol/L, respectively. According to
Student’s t-test it is statistically significant that the pa-
tients receiving statins, compared to the patients who
were not receiving statins, have higher mean values of 3
out of 4 observed lipoproteins (Table 5). They did not dif-
fer significantly solely in the level of HDL-C.
Discussion
In this study we compared lipoprotein profile of two
groups of hemodialyzed patients, continental and mari-
time. Our goal was, as previously mentioned, to deter-
mine whether the studied groups differ in plasma lipo-
protein profile or not, and to what extent could those
differences be explained by differences in their dietary
habits. Nevertheless, adequate diet is the first step in
treatment of primary and secondary disorders of lipid
metabolism.
The results of the retrospectively conducted research
on selected hemodialyzed patients have shown that the
patients from the continental and maritime group signif-
icantly differ in types of food they consume, as well as ac-
cording to the methods of food preparation. Accoriding to
c2-test it is statistically significant that the patients from
the continental group eat more often pork, and prepared
their food using lard or sunflower oil. Significant was the
fact that the patients from the maritime group statisti-
cally more frequently eat fish and prepared their food by
cooking it or with olive oil (so-called »mediterranean cui-
sine«) (Table 2). Despite the significant differences in
their dietary habits, statistically, acoording to Student’s
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TABLE 4
BASIC CHARACTERISTICS OF TWO SUBGROUPS OF PATIENTS WITHOUT STATINS MEDICATION





X±SD range X±SD range
Tot.-C (mmol/L) 4.52±0.81 2.92–6.06 4.34±0.96 2.04–6.59 1.02
TGC (mmol/L) 1.59±0.87 0.64–6.22 1.79±0.86 0.68–4.07 1.17
HDL-C (mmol/L) 1.16±0.45 0.62–3.70 1.17±0.55 0.55–3.98 0.10
LDL-C (mmol/L) 2.64±0.69 1.39–4.34 2.61±0.72 0.93–4.20 0.22
Tot.-C – total cholesterol, TGC – triglycerides, HDL-C – HDL-cholesterol, LDL-C – LDL-cholesterol
TABLE 5
BASIC CHARACTERISTICS OF TWO SUBGROUPS OF PATIENTS FORMED ACCORDING TO THE STATINS MEDICATION (A – PATIENTS





X±SD range X±SD range
Tot-C (mmol/L) 5.40±0.99 3.79–6.54 4.43±0.88 2.04–6.59 3.99**
TGC (mmol/L) 2.18±0.71 1.06–3.78 1.68±0.87 0.64–6.22 2.72**
HDL-C (mmol/L) 1.05±0.27 0.66–1.68 1.16±0.50 0.55–3.98 1.39
LDL-C (mmol/L) 3.29±0.74 2.07–4.49 2.63±0.70 0.93–4.34 3.60**
Tot-C – total cholesterol, TGC – triglycerides, HDL-C – HDL-cholesterol, LDL-cholesterol
** p<0.01
t-test the two groups of patients did not differ signifi-
cantly in mean values of TC, TGC, LDL-C i HDL-C (Ta-
ble 1). However, statistically, according to c2-test, there
were significantly more hemodialyzed patients from the
continental group receiving statins (Table 3).
Svensson and associates36 have explored the influence
of frequency in food consumption on lipid profile of 206
patients receiving hemodialysis for a period longer than
6 months. According to frequency of fish consumption,
they were divided into three groups. In the first group
there were patients who consumed fish rarely, in the sec-
ond group those who consumed it moderately often, and
in the third those who consumed it very often. The more
frequently patients consumed fish, the more often they
had higher serum concentrations of two unsaturated
fatty acids, eicosapentaenoic (EPA) and docosahexaenoic
(DHA) acid, as well as lower values of TGC and higher of
TC, LDL-C i HDL-C. Introduction of omega-3 fatty acids,
comprising 45% EPA and 37.5% DHA, has resulted in
minimal decrease of TGC, TC and LDL-C as well as in-
crease of HDL-C; introduction of olive oil has resulted in
minimal decrease of TC and LDL-C, as well as increase of
TGC and HDL-C. Although fatty acids from fish oil can
lead to doubling of bleeding time, the use of fish oil has
not been followed by significant risk of bleeding37.
Cano et al.38 have studied the influence of olive oil and
soja oil administered in the form of lipid emulsion on the
nutritional status of a small group of patients undergo-
ing dialysis for longer than 6 months. They included pa-
tients with BMI under 20 kg/m2 body surface area, with
albumins below 35 g/L, prealbumin below 300 mg/L,
daily protein catabolic rate (nPCR) under 1 g/kg of body
weight, as well as those who manged to reduce their
weight by at least 10% during 6 months. After 5 weeks in
both groups there was a significant increase in TC and
LDL-C, and non-significant increase in TGC snd HDL-C.
However, regular intake of 25 mL of olive oil on daily ba-
sis did not have any significant influence on lipid profile
of healthy subjects39.
By studying the influence of diet on body weight in-
crease in hemodialyzed patients, Özdemir et al.40 have
concluded that patients (n=194) on Mediterranean diet
rich in seafood and vegetables significantly less increase
their body weight (2.47±0.94 kg) between two cycles of
hemodialysis in comparison to continental group of pa-
tients(n=508) (3.08±0.94 kg), whose food is rich in pro-
teins and carbohydrates. A group of Greek authors has
investigated the influence of Mediterranean diet on total
mortality, as well as mortality from coronary and malig-
nant diseases in total population. According to the types
of food they consume as well the frequency of consump-
tion, the subjects were divided into those that accept
Mediterranean diet partially and those that accept it al-
most completely. They have found that the subjects who
almost completely accept Mediterranean diet have by
25% lower total mortality, by 33% lower mortality rate
from coronary diseases, and by 24% lower mortality rate
from malignant diseases, compared to the subjects who
accept Mediterranean diet only partially (n=22043; fol-
low-up period: 44 months).
By researching possible influence of erythropoietin on
plasma lipid profile of dialyzed patients (n=33; females
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TABLE 6
MEAN TOTAL, LDL- AND HDL-CHOLESTEROL SERUM CONCENTRATIONS IN THE TWO HEMODIALYSIS PATIENTS GROUP







Tot. cholesterol – mmol/L 4.70±0.91 4.42±1.02 1.56 0.061
Decrease 10% 4.84±0.95 4.45±1.07 *2.07 0.020
Decrease 15% 4.92±0.99 4.46±1.13 *2.32 0.011
Decrease 20% 5.01±1.05 4.48±1.18 *2.55 0.006
Decrease 25% 5.12±1.09 4.50±1.23 *2.87 0.003
LDL – C – mmol/L 2.78±0.74 2.66±0.75 0.87 0.193
Decrease 10% 2.87±0.78 2.68±0.79 1.31 0.097
Decrease 15% 2.92±0.81 2.69±0.82 1.53 0.065
Decrease 20% 2.97±0.85 2.70±0.86 *1.71 0.045
Decrease 25% 3.04±0.89 2.71±0.90 *2.00 0.024
Decrease 30% 3.11±0.93 2.73±0.94 *2.22 0.014
Decrease 35% 3.19±0.96 2.75±0.97 *2.47 0.007
HDL – C – mmol/L 1.13±0.42 1.16±0.54 0.33 0.629
increase 10% 1.11±0.45 1.16±0.54 0.54 0.703
HDL-C – HDL-cholesterol, LDL-C – LDL-cholesterol
* statistical significant
22, males 11), Allegra et al.42 have found out that TC,
TGC, LDL-C and apolipoprotein B were increased only in
those patients (n=19) who during erythropoietin treat-
ment increased their daily calorie intake by more than
10%, due to increased intake of proteins, fats and carbo-
hydrates. Hence, the influence of diet on plasma lipopro-
tein profile of dialyzed patients can be stronger than the
influence of chronic renal failure itself and its methods of
treatment. Why such an influence has not been observed
in our study?
Analyses show that our two studied groups of patients
do not distinguish themselves only in dietary habits, but
also according to frequency of statin taking. The results
of numerous studies have indicated that statins decrease
LDL-C by 25–40% in patients suffering from final stage
CRF43–47, similar as in patients without CRF20,48. In the
famous »4 S Study«, which included 4444 patients with
TC between 5.5 and 8.0 mmol/L, the treatment with
simvastatin has resulted in mean decrease of TC by 25%,
LDL-C by 35%, as well as increase of HDL-C by 8%17.
Statins do not normalize plasma lipoproteins in all pa-
tients who take them. For that reason, 19 of our patients
treated with statins statistically have significantly hig-
her mean values of TC, TGC and LDL-C compared to pa-
tients who did not receive statins. Their HDL-C is indeed
lower, but statistically not significantly lower (Table 5).
Under presumption that statins were equally efficient
in our patients who received them, as they were for »4 S
Study«17 patients, then, without them, patients from the
continental group would have TC 5.12±1.09 mmol/L,
LDL-C 3.19±0.96 mmol/L, and HDL-C 1.11±0.45 mmol/L.
The patients from the maritime group would have TC
4.50±1.23 mmol/L, LDL-C 2.75±0.97 mmol/L, and HDL-C
1.16±0.54 mmol/L. According to t-test statistically there
should be significant differences in mean values of TC
and LDL-C, but not of HDL-C (Table 6). Or, to para-
phrase it: statin-caused TC decrease by 10% and LDL-C
by 20% is enough to eliminate value differences when
comparing two groups of patients.
When analyzing both of our groups together, it is obvi-
ous that almost every 7th subject takes statins (13.93%).
For the purpose of comparison, it should be stated that
according to Seliger and associates21 less than 10% of
their dialyzed patients received statins at the beginning
of the treatment using this method; which is signifi-
cantly more compared to our patients from the maritime
group (4%), and significantly less compared to our pa-
tients from the continental group (23.61%). In DOPPS,
already mentioned in Introduction, during the year 2000
in 7 countries 11.80% of dialyzed patients have received
statins; from 3.5–5% in Italy and Japan to 12–17% in
Germany, France and United States of America22.
In the conclusion, based on the results obtained from
our study, we can state that diet significantly influences
the lipid profile of dialyzed patients. Namely, the patients
from the continental group plasma lipoprotein values
similar to the patients from the maritime group, from
which they significantly differ in dietary habits, only
thanks to significantly more frequent taking of statins.
The influence of final stage CRF and hemodialysis as
method of treatment are not more dominant in compari-
son to dietary habits.
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JESU LI POREME]AJI LIPOPROTEINA PLAZME HEMODIJALIZIRANIH BOLESNIKA
POSLJEDICA SAMO BUBRE@NOG ZATAJENJA?
S A @ E T A K
Hemodijalizirani bolesnici imaju ~esto kvantitativne, a jo{ ~e{}e kvalitativne poreme}aje serumskih lipida. Naj~e{}e
su im povi{eni trigliceridi i VLDL-kolesterol, mini-malno povi{en ili normalan ukupni i LDL-kolesterol i sni`en HDL-
-kolesterol. U ovom radu uspore|ivali smo lipidni profil dvije skupine hemodijaliziranih bolesni-ka, jedne iz kontinen-
talnog, a druge iz primorskog dijela zemlje. Cilj nam je bio odrediti je li na njihov lipidni profil utje~u razlike u njihovoj
prehrani. U istra`ivanje su uklju~ena 72 bolesnika iz kontinentalnog (m-39) i 50 iz primorskog dijela zemlje (m-30).
Nisu bili uklju~eni {e}erni bolesnici, bolesnici s hipotireozom, jetrenim bolestima, alkoholi~ari i bolesnici lije~eni sevela-
merom. Svakom bolesniku, uz osnovne po-datke, odre|en je nata{te, prije redovite hemodijalize, niz laboratorijskih
parametara. Svi su bolesnici dijalizirani bikarbonatnom hemodijalizom polisulfonskim dijalizatorima niske permeabil-
nosti. Bolesnici kontinentalne skupine bili su ne{to stariji, dulje lije~eni ponavljanim hemo-dijalizama, ni`i, te`i, ve}eg
indeksa tjelesne mase, vi{eg ukupnog (4,70±0,91:4,42±1,02 mmol/L) i LDL-kolesterola (2,78±0,74:2,66±0,75 mmol/L), a
ni`ih triglicerida (1,72±0,84:1,81±0,83 mmol/L) i HDL-kolesterola (1,13±0,42:1,16±0,54 mmol/L), ali bez statisti~ki zna-
~ajne razlike. Prema c2-testu ~e{}e su jeli svinjsko meso, slaninu, suhomesnate proizvode, margarin, maslac, orahe,
bademe, ~e{njak, vrhnje i punomasne sireve, a rije|e ribu. Hranu su zna~ajno ~e{}e pri-premali na svinjskoj masti i
suncokretovom ulju. Skoro svaki 4. bolesnik kontinentalne skupi-ne uzimao je statine, a samo svaki 25. iz primorske
skupine bolesnika. Prema c2-testu u pod-skupinama bolesnika nije bilo razlike udjela onih sa ukupnim kolesterolom
iznad 5,20 mmol/L, trigliceridima iznad 1,60 mmol/L, HDL-kolesterolom ispod 1,10 mmol/L, LDL kolesterolom iznad
2,60 mmol/L, pretilih, a ni pothranjenih bolesnika. U zaklju~ku mo`emo, na osnovi rezultata dobivenih na{im ispiti-
vanjem re}i da prehra-na ipak bitno utje~e na lipidni profil hemodijaliziranih bolesnika. Naime, bolesnici kontinen-
-talne skupine imaju lipoproteine plazme vrlo sli~ne lipoproteinima plazme bolesnika primor-ske skupine, od koji se
zna~ajno razlikuju po prehrani, samo zahvaljuju}i zna~ajno ~e{}em uzimanju statina. Utjecaj zavr{nog stadija KBZ i
hemodijalize kao metode lije~enja nije dominantniji od prehrane.
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